In 2021, the market for gene therapy was estimated to be worth US$1.55 billion. The market is anticipated to expand at a CAGR of 18.5% between 2022 and 2032, rising from US$ 1.85 billion to US$ 10.1 billion.
The prevalence of rare disorders has significantly increased, which has increased demand for cell and gene therapy. Ex-vivo gene therapy is gaining acceptance for neurological therapies, which is anticipated to fuel market expansion for gene therapy until 2032.
For more insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4648?SP
The readability score of the Gene Therapy Demand report is good as it offers chapter-wise layout with each section divided into a smaller sections.
The report encompasses graphs and tables to show the entire assembling. Pictorial demonstration of the definite and estimated values of key segments is visually appealing to readers.
This Gene Therapy outlook report explicates on vital dynamics such as the drivers, restraints and opportunities for key players and competitive analysis of Silage Covers along with key stakeholders as well as emerging players associated with the manufacturing of product.
Competitive Landscape:
The global gene therapy market is fiercely competitive, with only a few major players. Companies like Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., have a sizable market share in the Gene Therapy market. To secure a position in the global market, various strategic alliances such as collaborations, acquisitions, and the launch of advanced products have been formed.
- In October 2021, the National Institutes of Health, the United States Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations announced a collaboration to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease. Such initiatives are expected to boost demand for gene therapy.
- BioMarin Pharmaceutical Inc. reported updates on its investigational gene therapy programs in clinical development in February 2022. The Food and Drug Administration (FDA) issued additional requests to the Company for information needed to resolve the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021.
- Novartis acquired Gyroscope Therapeutics in December 2021, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness.
- Abecma (idecabtagene vicleucel), a cell-based gene therapy, was approved by the US Food and Drug Administration in March 2021 to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the first FDA-approved cell-based gene therapy for the treatment of multiple myeloma.
Key Segments Covered in Gene Therapy Industry Research:
· By Product :
- Yescarta-based
- Kymriah-based
- Luxturna-based
- Strimvelis-based
- Gendicine
- Others
· By Application :
- Ophthalmology
- Oncology
- Adenosine Deaminase/Deficient Severe Combined Immunodeficiency (ADA-SCID)
· By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- MEA
For in-depth competitive analysis, Buy Now:
https://www.factmr.com/checkout/4648
Questionnaire answered in the Market outlook Report of Gene Therapy include:
- What is the key strategy deployed by large players to maximize Gene Therapy growth?
- What are the main challenges faced by players in the Gene Therapy Demand?
- With the advent of technological advancement, how will the Gene Therapy landscape change over the forecast period?
- What does player bring to the table which is unique as a strategy, and is easy to emulate for new investors in the Gene Therapy size?
Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: [email protected]